Taro Hirai

Dr. Taro Hirai

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JXJing Xu
Jing Xu
THTaro Hirai
Taro Hirai
DKDaisuke Koya
Daisuke Koya
MKMunehiro Kitada
Munehiro Kitada
Atherosclerosis-caused cardiovascular diseases (CVD) are the leading cause of mortality in type 2 diabetes mellitus (T2DM). Sodium-glucose cotransporter 2 (SGLT2) inhibitors are effective oral drugs for the treatment of T2DM patients. Multiple pre-clinical and clinical studies have indicated that SGLT2 inhibitors not only reduce blood glucose but also confer benefits with regard to body weight, insulin resistance, lipid profiles and blood pressure. Recently, some cardiovascular outcome trials have demonstrated the safety and cardiovascular benefits of SGLT2 inhibitors beyond glycemic control. The SGLT2 inhibitors empagliflozin, canagliflozin, dapagliflozin and ertugliflozin reduce the rates of major adverse cardiovascular events and of hospitalization for heart failure in T2DM patients regardless of CVD. The potential mechanisms of SGLT2 inhibitors on cardioprotection may be involved in improving the function of vascular endothelial cells, suppressing oxidative stress, inhibiting inflammation and regulating autophagy, which further protect from the progression of atherosclerosis. Here, we summarized the pre-clinical and clinical evidence of SGLT2 inhibitors on cardioprotection and discussed the potential molecular mechanisms of SGLT2 inhibitors in preventing the pathogenesis of atherosclerosis and CVD.

8 January 2021 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
PDF file
THTaro Hirai
Taro Hirai
MKMunehiro Kitada
Munehiro Kitada
IMItaru Monno
Itaru Monno
EOErina Oda
Erina Oda
YHYoshihiro Hayashi
Yoshihiro Hayashi
DKDaisuke Koya
Daisuke Koya
Introduction The aim of this study is to elucidate whether SGLT2is treatment has any renoprotective effect for type 2 diabetic (T2DM) patients with an estimated glomerular filtration rate (eGFR) of < 60 ml/min/1.73m2, in clinical practice. Research design and methods We evaluated the annual eGFR slope in 85 T2DM patients with renal impairment, treated with SGLT2is ≥ 2 years. Each patient's eGFR was < 60 ml/min/1.73m2 at the start of SGLT2is therapy. The calculation of the annual change in eGFR for each patient was obtained by acquired eGFR data before and after 2 years of the initial SGLT2is administration, followed by analysis of the changes in the mean eGFR slope. Results The participants' mean age was 72.0 ± 9.4 years old, and the mean eGFR was 47.1 ± 9.7 ml/min/1.73m2 at the start of additional treatment with SGLT2is. Mean annual eGFR slope after SGLT2is administration (−0.11 ± 0.20 ml/min/1.73m2/year) was significantly slower than before SGLT2is administration (−2.93 ± 0.59 ml/min/1.73m2/year) (p < 0.0001). Additionally, SGLT2is treatment slowed the annual decline of eGFR, independent of the levels of both the initial eGFR and albuminuria levels before SGLT2is therapy was started. In the patient groups who showed an annual eGFR decline of ≥ 3 and 1–3 ml/min/1.73m2, there was a significant slowing of the decline after SGLT2is therapy, compared to before the treatment (p < 0.001, respectively). Conclusions SGLT2is administration slows the decline observed in the annual renal function in T2DM patients with eGFR of < 60 ml/min/1.73m2, in clinical practice.

5 February 2020 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
PDF file
THTaro Hirai
Taro Hirai
MKMunehiro Kitada
Munehiro Kitada
YHYoshihiro Hayashi
Yoshihiro Hayashi
IMItaru Monno
Itaru Monno
YTYuta Takagaki
Yuta Takagaki
DKDaisuke Koya
Daisuke Koya
A 58‐year‐old women who was diagnosed with type 2 diabetes 20 years earlier had been treated with antidiabetic medicines since she was aged 40 years. After sodium–glucose cotransporter 2 inhibitors administration, her bodyweight rapidly decreased from 40 to 30 kg over a period of 3 weeks. She had abdominal symptoms, including nausea, especially after a meal. On admission, physical examinations and laboratory data showed euglycemic ketoacidosis, dehydration and low insulin secretion levels. Additionally, abdominal contrast computed tomography showed the finding of superior mesenteric artery syndrome. This case urges caution, including rapid excessive bodyweight loss and euglycemic ketoacidosis, on the use of sodium–glucose cotransporter 2 for lean diabetes patients.

19 August 2025 in Journal of the Endocrine Society
Verified
Journal Article
Open access
KTKeisuke Takano
Keisuke Takano
KHKoichi Hayashi
Koichi Hayashi
KKKoichi Kitamura
Koichi Kitamura
MKMutsuo Kanda
Mutsuo Kanda
KIKei Ito
Kei Ito
TSToshihiko Suzuki
Toshihiko Suzuki
Context: The fibrosis-4 (FIB-4) index is a noninvasive marker for liver fibrosis and is associated with the occurrence of diabetic kidney disease (DKD). Although sodium-glucose cotransporter-2 inhibitors (SGLT2is) are recognized to provide cardiovascular and renal benefits, the role of SGLT2is in regulating FIB-4 index and the subsequent effect on renal events remain unclear. Objective: This work aimed to clarify whether the FIB-4 index was associated with the development of DKD (estimated glomerular filtration rate < 60 mL/min/1.73 m2 or new-onset macroalbuminuria) and whether the background treatment with other antidiabetic drugs modified the effects of SGLT2i on FIB-4 index and renal events. Methods: A retrospective cohort study was conducted that included 136 patients with type 2 diabetes mellitus who were newly given SGLT2is for 3 years. Results: Patients with a high FIB-4 index (≥1.3) at baseline exhibited a higher incidence of de novo DKD, compared to those with a lower FIB-4 index (<1.3). This association was ameliorated in patients whose FIB-4 index was decreased during the SGLT2i treatment. Finally, among the background therapies, metformin use was associated with a decrease in FIB-4 index and a lower cumulative incidence of de novo DKD. Conclusion: Elevated FIB-4 index at baseline is a potent predictor for developing DKD, and combination therapy with SGLT2is and metformin may enhance renal protection by modulating FIB-4 index.

31 January 2022 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
PDF file
KSKeiji Shimada
Keiji Shimada
KKKeizo Kanasaki
Keizo Kanasaki
MKMakoto Kato
Makoto Kato
YOYoshio Ogura
Yoshio Ogura
YTYuta Takagaki
Yuta Takagaki
DKDaisuke Koya
Daisuke Koya
Aims/Introduction A sodium glucose cotransporter 2 inhibitor (SGLT2i) has shown to display excellent renoprotective effects in DKD with macroalbuminuria/proteinuria. Regarding the renoprotective mechanism of SGLT2i, a sophisticated hypothesis was made by explaining the suppression of glomerular hypertension/hyperfiltration via the adenosine/adenosine type 1 receptor (A1R) signaling-mediated restoration of the tubulo-glomerular feedback mechanism; however, such A1R signaling is relevant for renoprotection by SGLT2i in DKD with proteinuria has not been elucidated. Materials and Methods STZ induced diabetic CD-1 mice were injected with bovine serum albumin (BSA) and ​treated with SGLT2i in the presence/absence of AIR inhibitor administration. Results We found that the influences of SGLT2i are essentially independent of the activation of A1R signaling in the kidney of BSA-overloaded streptozotocin-induced diabetic mice. BSA-overloaded diabetic mice displayed trend of kidney damage with higher glomerular filtration (GFR) and the significant induction of fibrogenic genes such as transforming growth factor (TGF)- β2 and collagen type III (COL3). SGLT2i TA-1887 suppressed diabetes-induced GFR in BSA-overloaded diabetic mice associated with the significant suppression of TGF-β2 and COL3; A1R-specific inhibitor 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) did not cancel the effects of TA-1887 on either GFR or associated gene levels. Both TA-1887 and DPCPX-treated BSA-overloaded diabetic mice displayed suppressed HbA1c levels associated with the increased food intake. When analyzing the association among histological evaluation, GFR and potential fibrogenic gene levels, each group of mice displayed distinct correlation patterns. Conclusions A1R signaling activation was not the dominant mechanism on the influence of SGLT2 inhibitor in the kidney of BSA-overloaded diabetic mice.